{
    "clinical_study": {
        "@rank": "1464", 
        "acronym": "NIS-OvaYond", 
        "arm_group": {
            "arm_group_label": "Yondelis-Pegylated liposomal Doxorubicin", 
            "description": "30 mg/m\u00b2 PLD i.v. followed by 1.1 mg/m\u00b2 Yondelis\u00ae i.v. 3 h, q3weeks"
        }, 
        "brief_summary": {
            "textblock": "Clinical trials are, due to the inclusion and exclusion criteria, accomplished with defined\n      patient groups, which are not representative for the whole patient population.\n\n      Especially elderly patients and patients with co-morbidities are underrepresented in\n      clinical trials.\n\n      This non-interventional study will examine the efficiency and toxicity of the Yondelis\u00ae +\n      PLD combination therapy in a general patient population to evaluate if the data collected in\n      the clinical trials can be assigned to a general patient population."
        }, 
        "brief_title": "An Observational Study of YONDELIS\u00ae+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Ovarian Cancer", 
        "condition_browse": {
            "mesh_term": "Ovarian Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Yondelis\u00ae (trabectedin) was approved (in combination with PLD) in the European community in\n      December 2009 for the treatment of platinum-sensitive ovarian cancer relapse. Based on the\n      outcomes of study OVA-301, this non-interventional study will investigate the role of a\n      platinum-free treatment regimen in patients with progressive ovarian cancer relapsing > 6\n      months after completing previous platinum-based chemotherapy. In particular, this study aims\n      at collecting the \"real-life\" data with regard to the response and the influence of the\n      mentioned therapy on the \"tumor related events\", to objectify the value of palliative care."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women age >18, no upper limit\n\n          -  Patients with relapsed platinum-sensitive ovarian cancer\n\n          -  Before inclusion in the NIS written informed consent must be given\n\n        Exclusion Criteria:\n\n          -  According to summary of product characteristics"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "hospitales and medical practices in Germany"
            }
        }, 
        "enrollment": {
            "#text": "180", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01869400", 
            "org_study_id": "OvaYond"
        }, 
        "intervention_browse": {
            "mesh_term": "Trabectedin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Grafing", 
                    "country": "Germany", 
                    "state": "Bayern", 
                    "zip": "85567"
                }, 
                "name": "Praxis Dr. Gr\u00f6ll de Rivera"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational, Multicenter, Open-label Study of YONDELIS\u00ae+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer", 
        "overall_official": {
            "affiliation": "Klinikum der Friedrich-Schiller-Universit\u00e4t Jena, Klinik f\u00fcr Frauenheilkunde, Bachstr. 18, D-07743 Jena", 
            "last_name": "Ingo Runnebaum, Prof. Dr.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with adverse events", 
            "measure": "safety and tolerability data of the study therapy", 
            "safety_issue": "Yes", 
            "time_frame": "during Yondelis-PLD-therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01869400"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of patients with CR, PR, SD as best response", 
                "measure": "\"Real life data\" - clinical and / or serological (CA 125) response and Stable disease rates", 
                "safety_issue": "No", 
                "time_frame": "till one year after last date of Yondelis-PLD-therapy"
            }, 
            {
                "description": "Time between first and last cycle of each patient", 
                "measure": "Treatment duration", 
                "safety_issue": "No", 
                "time_frame": "during Yondelis-PLD-therapy"
            }, 
            {
                "measure": "Observation of the number of the therapy cycles applied", 
                "safety_issue": "No", 
                "time_frame": "during Yondelis-PLD-therapy"
            }, 
            {
                "measure": "Time to next treatment", 
                "safety_issue": "No", 
                "time_frame": "1 Year after last Yondelis-PLD-Therapy"
            }, 
            {
                "description": "Difference between date of first documentation of \"PD\" and the date of first Yondelis\u00ae + PLD application", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "till one year after last date of Yondelis-PLD-therapy"
            }, 
            {
                "description": "Time in months from first assessment of CR or PR until the first date of PD or death.", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "till one year after last date of Yondelis-PLD-therapy"
            }
        ], 
        "source": "PharmaMar, Spain", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "PharmaMar, Spain", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}